


Abstract of the disclosure

of the formula (IV):



5

where:

R1 = R'C(O) , R' SO2 ,

R' = a bicyclic, saturated or unsaturated, 8-12 membered ring system

10 containing 0-4 hetero atoms selected from S, O and N, which is optionally substituted with up to four substituents independently selected from groups a), b) and c) below; or

R'= a monocyclic, saturated or unsaturated, 5-7 membered ring containing 0-3 hetero atoms selected from S, O and N, which monocyclic ring bears at least 15 one substituent selected from group a) and/or c) and which may optionally bear one or two further substituents selected from group b);

R4 = H, C1-7-alkyl, Ar-C1-7-alkyl, Ar, C3-7-cycloalkyl; C2-7alkenyl,;

R3 = C1-7-alkyl, C2-C7 alkenyl, C2-C7 alkenyl, C3-7-cycloalkyl, Ar-C1-7-alkyl,

20 Ar;

R5 = C1-7-alkyl, halogen,Ar-C1-7-alkyl, C0-3-alkyl-CONR3R4 or a bulky amine

R6 is H, C1-7-alkyl, Ar-C1-7-alkyl, C1-3-alkyl-SO2-R^{ix}, C1-3-alkyl-C(O)-NHR^{ix} or CH₂XAr

25 q is 0 or 1

have utility as inhibitors of cysteine proteases such as cathepsin K and falcipain.